Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.59 |
| ▸ | CNR1 | P21554 | 9/20 | 0.41 |
| ▸ | CTSA | P10619 | 1/20 | 0.34 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4126695 | 1.00 | CNR2 (0.59) | CNR2CNR1CTSAMAP3K14PDE4A | |
| SCHEMBL1175838 | 0.95 | CNR2 (0.67) | CNR2CNR1CTSAMAP3K14 | |
| SCHEMBL1175841 | 0.95 | CNR2 (0.67) | CNR2CNR1CTSAMAP3K14 | |
| SCHEMBL4119545 | 0.94 | CNR2 (0.60) | CNR2CNR1PDE4APDE4BPDE4C | |
| SCHEMBL4119547 | 0.94 | CNR2 (0.60) | CNR2CNR1PDE4APDE4BPDE4C | |
| SCHEMBL4116988 | 0.90 | CNR2 (0.64) | CNR2CNR1MAP3K14 | |
| SCHEMBL4116982 | 0.90 | CNR2 (0.64) | CNR2CNR1MAP3K14 | |
| SCHEMBL1175013 | 0.89 | CNR2 (0.68) | CNR2CNR1PDE4APDE4BPDE4C | |
| SCHEMBL1175010 | 0.89 | CNR2 (0.68) | CNR2CNR1PDE4APDE4BPDE4C | |
| SCHEMBL1175825 | 0.89 | CNR2 (0.62) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | CNR2 2/4885CNR1 1/4885CTSA 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.